Policymakers, regulators, manufacturers, and health systems must navigate scientific complexity, supply-chain fragility, and evolving technologies to protect patients and promote innovation.
Key pillars of global regulation
– Quality and manufacturing standards: Good Manufacturing Practice (GMP) and inspection cooperation are central. International initiatives that promote mutual recognition or reliance of inspections help reduce duplication, accelerate approvals, and raise standards across markets.
– Safety and efficacy assessment: Harmonized clinical trial requirements and common technical documents streamline submissions. Pharmacovigilance networks collect post-market safety signals, enabling regulators to act quickly when adverse events emerge.
– Access and affordability: Balancing intellectual property incentives with public health needs remains a high-priority tension. Trade-related agreements and patent flexibilities influence countries’ options to adopt generics or grant compulsory licenses to address public health emergencies.
– Controlled substances and diversion prevention: International conventions and organizations coordinate to prevent illicit trafficking while ensuring legitimate medical access to opioids and other controlled medicines.
Mechanisms that enable global cooperation
– Harmonization and regulatory convergence: Frameworks that align technical requirements reduce time-to-market and lower development costs.
Convergence encourages predictable submission pathways for companies and clearer expectations for regulators.
– Regulatory reliance and recognition: Many regulators lean on trusted authorities’ assessments to make faster decisions, especially in resource-constrained settings. Reliance pathways and collaborative registration procedures expand access to quality-assured products without sacrificing review rigor.
– WHO prequalification and centralized programs: Prequalification programs and collaborative reviews provide quality assurance for products procured by international buyers, supporting use in public health programs and low-resource settings.
– International monitoring systems: Global safety databases enable signal detection across populations.
Sharing adverse event reports and safety communications improves risk management across jurisdictions.
Emerging challenges and priorities
– Strengthening regulatory capacity: Building scientific expertise, inspection capabilities, and digital infrastructure matters for consistent enforcement and faster approvals. Capacity-building partnerships are essential for regulatory maturity.
– Counterfeit and substandard medicines: Improved serialization, track-and-trace systems, and cross-border enforcement combat illicit supply. Public awareness and supply-chain transparency reduce patient risk.
– Digital health products and complex biologics: Regulators are adapting frameworks to address software-as-a-medical-device, digital therapeutics, and biosimilars. Clear guidance on clinical evidence, interoperability, and lifecycle management promotes safe adoption.
– Supply-chain resilience: Diversifying active pharmaceutical ingredient sources, adopting quality-by-design manufacturing, and maintaining strategic stockpiles reduce shortages and disruption risks.
– Data transparency and real-world evidence: Regulators increasingly accept real-world data for safety monitoring and supplemental indications. Clear standards for data quality and provenance are critical.
Action steps for policymakers and stakeholders
– Expand reliance-based pathways and bilateral agreements to speed access to quality products.
– Invest in regulatory workforce development and laboratory capacity to strengthen enforcement.
– Adopt digital track-and-trace and modern serialization across manufacturing and distribution.
– Harmonize guidance for digital therapeutics and real-world evidence to enable innovation.
– Enhance international cooperation to balance opioid access for pain management with diversion controls.
Robust international drug regulation protects patients and enables innovation. By combining harmonized standards, stronger regulatory capacity, and modern surveillance tools, stakeholders can improve medicine quality, expand access, and respond effectively to emerging threats across borders.